Clinical Trials Logo

Stroke, Ischemic clinical trials

View clinical trials related to Stroke, Ischemic.

Filter by:

NCT ID: NCT04393025 Completed - Stroke, Ischemic Clinical Trials

Endovascular Stenting of Medically Refractory ICASD (Clinical and Sonographic Study)

VasIntervent
Start date: June 2016
Phase: Phase 4
Study type: Interventional

Cerebral Endovascular Stenting of medically refractory Intracranial Stenotic Blood Vessels with Recurrent Ischemic Strokes patients

NCT ID: NCT04339699 Suspended - Stroke, Ischemic Clinical Trials

NobleStitch EL STITCH Trial is a PFO Comparative Trial

STITCH
Start date: January 1, 2021
Phase: N/A
Study type: Interventional

STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitchâ„¢ EL versus FDA-approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent Ischemic stroke.

NCT ID: NCT04332458 Completed - Stroke, Ischemic Clinical Trials

Motivators and Barriers for Physical Activity in Patients With Minor Stroke

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to investigate motivators and barriers for physical activity in patients discharged from hospital for a minor stroke or TIA. The study has a qualitative research design and will be conducted by focus group interviews.

NCT ID: NCT04330872 Completed - Stroke, Ischemic Clinical Trials

An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.

ECASIS
Start date: August 26, 2019
Phase: Phase 4
Study type: Interventional

Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the reduction of CV risk. We hypothesize that EC formulation based on the previous report may blunt aspirin response as evidenced by reduced Thromboxane A2 (TXA 2) levels in diabetic patients.

NCT ID: NCT04321512 Recruiting - Clinical trials for Myocardial Infarction

Study of Circulating Monocytes in Patients With Ischemic Vascular Disease

Start date: December 1, 2013
Phase:
Study type: Observational

The purpose of this research study is to discover the functions of circulating white blood cells, called monocytes, and associated circulating substances in heart attack and ischemic stroke patients. Ischemic Strokes (clots) occur as a result of an obstruction within a blood vessel supplying blood to the brain. A type of monocyte carrying a surface marker called "P2X4" helps the immune system sense and respond to danger signals from the body such as heart muscle and brain tissue injuries. The researchers expect to learn more about how these monocyte cells react to heart and brain tissue injury, and how the cells may then produce proteins or other chemical substances which promote the healing of heart muscle after heart attack and brain tissue after an ischemic stroke.

NCT ID: NCT04292600 Completed - Stroke, Ischemic Clinical Trials

Testing of Identification Markers for Stroke

TIME
Start date: May 1, 2021
Phase:
Study type: Observational

Stroke is the third leading cause of death and the first cause of physical disability and dementia worldwide. Ischemic stroke caused by large vessel occlusion (LVO) is responsible for the vast majority of deaths and disabilities. A very effective and safe treatment, called mechanical thrombectomy (MT) is available for LVO patients. Nevertheless, no blood biomarkers able to identify LVO patients rapidly and to direct them to CT angiography and thrombectomy currently exist. The TIME study is an observational prospective cohort study. All Patients referred to the emergency department or stroke unit with a suspected stroke as identified by paramedics, nurses or clinicians will be enrolled in the study. A panel of blood biomarkers will be analysed retrospectively via standard laboratory assays. The main outcome of the TIME study will be the evaluation of the clinical diagnostic performance of a panel of blood biomarkers, in conjunction with clinical data, for the identification of large vessel occlusion ischemic stroke subtype. This study will allow the identification and evaluation of a final panel of biomarkers and will prompt the development of a test for LVO stroke diagnosis.

NCT ID: NCT04287231 Completed - Stroke, Ischemic Clinical Trials

The Effect of The Five-Session Dual-tDCS On Lower-Limb Performance in Sub-Acute Stroke

Start date: August 19, 2019
Phase: N/A
Study type: Interventional

The aim of the present study is to determine the effect of the five-session dual-tDCS combine with physical therapy on gait performance, balance and lower limbs muscle strength in patients with subacute stroke.

NCT ID: NCT04282993 Recruiting - Atrial Fibrillation Clinical Trials

Wearable Devices for Secondary Prevention of Ischemic Stroke

Start date: April 16, 2019
Phase: N/A
Study type: Interventional

Ischemic stroke is an important cause of death and disability in Western countries. Different risk factors have been identified such as hypertension, diabetes, dyslipidemia, smoke, atrial fibrillation, obesity, and sedentary. The aim of this study is to evaluate the feasibility of an approach based on the use of wearable devices for the identification and reduction of risk factors in patients with previous history of ischemic stroke or transient ischemic attack.

NCT ID: NCT04265664 Completed - Stroke Clinical Trials

Telerehabilitation With Aims to Improve Lower Extremity Recovery Post-Stroke

TRAIL
Start date: July 28, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the feasibility and effectiveness of a lower extremity telerehabilitation protocol with aims to improve lower extremity recovery among community-living stroke survivors across Canada.

NCT ID: NCT04256096 Recruiting - Stroke, Ischemic Clinical Trials

Randomization of Endovascular Treatment in Acute Ischemic Stroke in the Extended Time Window

RESILIENTExt
Start date: March 9, 2020
Phase: Phase 3
Study type: Interventional

A phase III, randomized, multi-center, open label clinical trial that will examine whether endovascular treatment is superior to standard medical therapy alone in patients who suffer a large vessel anterior circulation ischemic stroke within 8-24 hours from time last seen well